Elotuzumab: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Elotuzumab. Educational only — not medical advice.
Labeled uses
• EMPLICITI is indicated in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one to three prior therapies. • EMPLICITI is indicated in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.
Source: FDA labeling via NIH DailyMed (set 80686b7e…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.